Table 2 Tumour RECIST response rates at 8 and 16 weeks.

From: Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

 

Target cancer site

All

Ovarian cancer

Breast cancer

Timepoint

Response

N = 67

N = 57

N = 10

No.

%

No.

%

No.

%

8 weeks

CBR (CR, PR and SD)

22

33

17

30

5

50

CR

0

0

0

0

0

0

PR

1

1

0

0

1

10

SD

21

31

17

30

4

40

PD

22

33

18

32

4

40

Withdrew prior to scan

23

34

22

39

1

10

16 weeks

Objective response (CR, PR and SD)

12

18

8

14

4

40

CR

0

0

0

0

0

0

PR

0

0

0

0

0

0

SD

12

18

8

14

4

40

PD

6

9

5

9

1

10

Withdrew prior to scan

49

73

44

77

5

50

  1. CBR clinical benefit rate, CR complete response, PR partial response, SD stable disease, PD progressive disease